References

Collier T, Smith S, Greenwood M, Ng K. Living with advanced hormone-sensitive prostate cancer and treatment with abiraterone and androgen deprivation therapy: the patient, nursing and physician perspective. Oncol Ther.. 2020; 8:(2)197-207 https://doi.org/10.1007/s40487-020-00132-22

Kamen C, Alpert A, Margolies L ‘Treat us with dignity’: a qualitative study of the experiences and recommendations of lesbian, gay, bisexual, transgender, and queer (LGBTQ) patients with cancer. Support Care Cancer.. 2019; 27:(7)2525-2532 https://doi.org/10.1007/s00520-018-4535-0

Ng K, Wilson P, Mutsvangwa K, Hounsome L, Shamash J. Over-all survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20 year retrospective analysis in the largest healthcare trust in England. Prostate Cancer Prostatic Dis.. 2021; https://doi.org/10.1038/s41391-020-00316-x

Prostate Cancer UK. Making the case for CNSs. 2019. https://prostatecanceruk.org/for-health-professionals/making-the-case-for-clinical-nurse-specialists (accessed 29 April 2021)

Pugh G, Hough R, Gravestock H, Fisher A. The health behaviour status of teenage and young adult cancer patients and survivors in the United Kingdom. Support Care Cancer.. 2019; 28:(2)767-777 https://doi.org/10.1007/s00520-019-

Reflections on a uro-oncology clinical nurse specialist training post

13 May 2021
6 min read
Volume 30 · Issue 9

Being new to the role of clinical nurse specialist over the last 6 months, I have discovered that the scope of this role is huge. The role of uro-oncology clinical nurse specialists (CNSs) is to support any patients who have a diagnosis of a urological cancer: testicular, prostate, penile, ureteric, kidney or bladder cancer, basically any part of the urological system. In this article I will try to give a snapshot of our role at my hospital and the work we do caring for patients with metastatic disease.

On referral to St Bartholomew's Hospital, the patient will be reviewed by their consultant: Dr Shamash, Dr Alifrangis or Professor Powles depending on the tumour type. Dr Shamash and Dr Alifrangis cover the super-regional Germ Cell Network as we are the tertiary referral service for East Anglia, seeing 200 new patients each year and reviewing just under 300 cases over a year at the multidisciplinary team (MDT) meetings. Both consultants review all the metastatic prostate cancer patients from the five hospitals within Barts Health NHS Trust. Professor Powles receives all the bladder and renal cancer patients from North East London and runs the tertiary referral service for these tumour sites. He runs an extensive number of trials, which enhances their treatment lines.

Register now to continue reading

Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • Unlimited access to the latest news, blogs and video content